Skye Bioscience, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stockholders'Deficit and Preferred Stock Subject to Redemption (Tables)

Stockholders'Deficit and Preferred Stock Subject to Redemption (Tables)

3 Months Ended

Mar. 31, 2017

Equity [Abstract]

Schedule of summary of stock option activity

								Amount
		Exercise			Term			Issued and
Source		Price			(Years)			Outstanding

Pre 2015 Common Stock Warrants		$1.00			6-10				4,000,000
2015 Common Stock Warrants		$1.15-$5.00			5-10				442,000
2015 Series B Financing (see Note 6)
Common Stock Warrants to Series B Stockholders		$0.25			5				6,250,000
Placement Agent Warrants		$0.25			5				187,500
2016 Common Stock Warrants to Service Providers		$1.15			10				40,000
2016 Series C Placement Agent Warrants		$0.40			5				125,000
2017 Series D Placement Agent Warrants		$0.25			5				480,000
2017 Common Stock Warrants to Service Providers		$0.41			10				125,000

Total warrants outstanding as of March 31, 2017									11,649,500

Schedule of weighted average assumptions for employee options

						Options Outstanding
		Shares Available												Weighted
		for Grant of												Average
		Options &				Number of				Price per				Exercise
		Shares				Shares				Share				Price
Balance at December 31, 2016			857,500				1,142,500			$	0.42-3.00			$	0.61
Options granted			-				-			$	-			$	-
Options exercised			-				-			$	-			$	-
Options cancelled			12,500				(12,500	)		$	1.15			$	1.15
Balance at March 31, 2017			870,000				1,130,000			$	0.42-3.00			$	0.60
Vested and Exercisable at March 31, 2017							444,000			$	0.42-3.00			$	0.56